Thermo Fisher Scientific filings document operating results, material agreements, governance matters and capital-structure disclosures for a global supplier of scientific instruments, laboratory products, diagnostics, life science tools and pharmaceutical services. Recent Form 8-K reports include quarterly and annual results, acquisition-related events and definitive agreements.
The company’s proxy materials cover shareholder voting and board-governance matters. Its securities disclosures identify common stock and multiple NYSE-listed senior note classes, while Form 25 filings document removal from listing and registration for specific senior notes. The filing record also includes risk-factor and corporate disclosure categories tied to Thermo Fisher’s operating businesses and financing structure.
Gianluca Pettiti submitted a Form 144 notice indicating 400 shares of Common Stock tied to a restricted stock vesting on 02/28/2024 are being offered for sale. The filing lists a brokerage account at Fidelity Brokerage Services LLC and shows a prior sale of 400 shares on 02/09/2026 for $216,480.00.
Thermo Fisher Scientific Inc. reported solid first quarter 2026 results, with revenue up 6% to $11.01 billion and organic revenue growth of 1%. GAAP diluted EPS rose 11% to $4.43, while adjusted EPS increased 6% to $5.44, reflecting higher operating income and slightly improved GAAP operating margin of 16.9%.
Adjusted operating income grew to $2.40 billion with an adjusted operating margin of 21.8%. Free cash flow more than doubled to $825 million. The company completed the acquisition of Clario, repurchased $3.0 billion of stock, increased its dividend by 10%, and continued launching new products and strategic collaborations.
Thermo Fisher Scientific is asking shareholders to vote on electing 11 directors, approving an advisory say‑on‑pay resolution, and ratifying its independent auditors at the 2026 virtual annual meeting. The proxy highlights 2025 results, with revenue up 4% to $44.56 billion, GAAP diluted EPS rising 7% to $17.74, adjusted EPS of $22.87, and free cash flow of $6.34 billion. The company deployed about $16.5 billion of capital, including $13 billion for M&A such as the Filtration and Separation business from Solventum and an agreement to acquire Clario, and returned $3.6 billion via buybacks and dividends, achieving 11.3% adjusted ROIC. The Board emphasizes strong governance, active refreshment, and extensive shareholder engagement after only about 36% support on the 2025 say‑on‑pay vote, leading to 2026 compensation design changes and a long‑dated, performance‑based CEO retention grant tied to relative TSR versus the S&P 500.
SPERLING SCOTT M reported acquisition or exercise transactions in this Form 4 filing.
Thermo Fisher Scientific director Scott M. Sperling received a grant of 89.780 Phantom Stock Units, each convertible into one share of Common Stock. The units were credited on the director’s deferred compensation account at a price of $473.36 per unit under the company’s Deferred Compensation Plan for Directors.
Following this grant, Sperling now holds a total of 17,591.800 stock units in this account. These units are scheduled to be distributed in shares of Common Stock when his board service ends for any reason or if there is a change of control.
Keith R. Alexandra reported acquisition or exercise transactions in this Form 4 filing.
Thermo Fisher Scientific director Keith R. Alexandra received a grant of 66.02 Phantom Stock Units tied to common shares. These units were credited on March 28, 2026 at a reference price of $473.36 per unit under the company’s Deferred Compensation Plan for Directors. Each unit is convertible into one share of common stock and is distributable as stock when his board service ends or upon a change of control. Following this grant, Alexandra holds a total of 1,270.44 Phantom Stock Units directly.
Lynch Karen S reported acquisition or exercise transactions in this Form 4 filing.
Thermo Fisher Scientific director Karen S. Lynch received 66.02 Phantom Stock Units tied to common stock as deferred compensation. These units are credited under the company’s Deferred Compensation Plan for Directors at $473.36 per unit and are convertible into common stock on a 1-for-1 basis.
Following this grant, Lynch holds a total of 291.49 phantom units. The units are scheduled to be distributed in stock after her board service ends for any reason or upon a change of control, aligning compensation with long-term shareholder value.
JOHNSON JENNIFER M reported acquisition or exercise transactions in this Form 4 filing.
THERMO FISHER SCIENTIFIC INC. director Jennifer M. Johnson received a grant of 66.0200 Phantom Stock Units on March 28, 2026. These units are convertible into Common Stock on a 1-for-1 basis and were credited at $473.36 per unit under the Deferred Compensation Plan for Directors.
Following this grant, Johnson holds a total of 661.3100 Phantom Stock Units. Directors’ retainers are deferred quarterly as Common Stock units based on the closing stock price at quarter end, with shares distributed as stock after director service ends or upon a change of control.
WEISLER DION J reported acquisition or exercise transactions in this Form 4 filing.
Thermo Fisher Scientific director Dion J. Weisler received a grant of 79.2200 Phantom Stock Units on March 28, 2026, as a deferred director retainer. These units are credited under the company’s Deferred Compensation Plan for Directors at a price of $473.36 per unit and are convertible into Common Stock on a 1-for-1 basis. Following this award, Weisler holds a total of 2,717.8900 phantom stock units, which will be distributable as company stock when his board service ends or if there is a change of control.
Thermo Fisher Scientific Inc: The Vanguard Group filed Amendment No. 10 to its Schedule 13G/A reporting that it beneficially owns 0 shares of Thermo Fisher common stock, representing 0% of the class as reported. The amendment follows an internal realignment on January 12, 2026 under SEC Release No. 34-39538 that caused certain Vanguard subsidiaries and business divisions to report ownership separately.
The filing is signed by Ashley Grim, Head of Global Fund Administration, dated 03/27/2026. The filing states the disaggregated entities pursue the same investment strategies previously pursued by The Vanguard Group, Inc.